- Home
- TWO vs CVAC Comparison
TWO vs CVAC Comparison
Compare TWO & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- CVAC
- Stock Information
- Founded
- TWO 2009
- CVAC 2000
- Country
- TWO United States
- CVAC Germany
- Employees
- TWO N/A
- CVAC N/A
- Industry
- TWO Real Estate Investment Trusts
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- CVAC Health Care
- Exchange
- TWO Nasdaq
- CVAC Nasdaq
- Market Cap
- TWO 1.0B
- CVAC 1.2B
- IPO Year
- TWO 2009
- CVAC 2020
- Fundamental
- Price
- TWO $9.62
- CVAC $5.36
- Analyst Decision
- TWO Buy
- CVAC Hold
- Analyst Count
- TWO 8
- CVAC 3
- Target Price
- TWO $12.50
- CVAC $6.83
- AVG Volume (30 Days)
- TWO 1.9M
- CVAC 420.0K
- Earning Date
- TWO 10-27-2025
- CVAC 11-11-2025
- Dividend Yield
- TWO 16.22%
- CVAC N/A
- EPS Growth
- TWO N/A
- CVAC N/A
- EPS
- TWO N/A
- CVAC 1.01
- Revenue
- TWO $257,735,000.00
- CVAC $599,540,810.00
- Revenue This Year
- TWO N/A
- CVAC N/A
- Revenue Next Year
- TWO N/A
- CVAC $23.83
- P/E Ratio
- TWO N/A
- CVAC $5.33
- Revenue Growth
- TWO N/A
- CVAC 675.15
- 52 Week Low
- TWO $9.49
- CVAC $2.37
- 52 Week High
- TWO $14.28
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- TWO 43.08
- CVAC 45.73
- Support Level
- TWO $9.65
- CVAC $5.34
- Resistance Level
- TWO $9.92
- CVAC $5.41
- Average True Range (ATR)
- TWO 0.21
- CVAC 0.04
- MACD
- TWO -0.02
- CVAC -0.00
- Stochastic Oscillator
- TWO 15.75
- CVAC 18.18
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.